Safety Study of NHL With 90Y-hLL2 IgG

Status Completed

Clinical Trial Summary

This will be an open label, multiple center, non-randomized, dose-escalation Phase I/II trial, designed to evaluate the safety and effectiveness of a repeated, outpatient regimen utilizing IMMU-hLL2 intact monoclonal antibody IgG labeled with different doses of 90Y for the treatment of patients B-cell lymphoma (NHL).

Clinical Trial Description

90Y-labeled hLL2 will be administered according to a schedule based upon whether or not a patient had prior high-dose chemotherapy with a marrow or stem cell transplant. Patients with both indolent and aggressive types of NHL will be enrolled at each dose level without segregation. However, at the conclusion of the trial, with the maximum tolerated dose (MTD) defined, a minimum number of 6 patients with indolent NHL, 6 patients with aggressive NHL, and 6 patients with >25% bone marrow involvement will be studied at that dose level. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00421395
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	August 2002
Completion date	October 2007

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04240704` - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL	Phase 1
Active, not recruiting	`NCT04188678` - Resiliency in Older Adults Undergoing Bone Marrow Transplant	N/A
Recruiting	`NCT00807196` - Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma	Phase 1/Phase 2
Completed	`NCT00764829` - Blood Samples to Evaluate Biomarkers of Donor Chimerism	N/A
Completed	`NCT00726934` - The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients	N/A
Completed	`NCT01517581` - Brown Fat Activity and White Fat Accumulation	N/A
Completed	`NCT00193505` - Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma	Phase 2
Terminated	`NCT01744912` - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Phase 1
Terminated	`NCT01500161` - Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match	Phase 2
Active, not recruiting	`NCT03533283` - An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT00001379` - Treatment and Natural History Study of Lymphomatoid Granulomatosis	Phase 2
Completed	`NCT00574730` - CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma	N/A
Completed	`NCT00901225` - Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant	Phase 2
Terminated	`NCT01598025` - Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor	N/A
Terminated	`NCT01326728` - Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Completed	`NCT01290549` - A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma	Phase 1
Completed	`NCT00837200` - Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies	Phase 2
Completed	`NCT00807677` - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies	Phase 1
Terminated	`NCT00054834` - Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma	Phase 1
Terminated	`NCT00003500` - Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma	Phase 2